Study Comparing Contact X-ray Brachytherapy Versus Waiting Longer and Local Excision for Preserving the Rectum in Patients With Good Response After Chemoradiation for Rectal Cancer
Led by The Netherlands Cancer Institute · Updated on 2023-03-17
168
Participants Needed
7
Research Sites
208 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are exploring ways to preserve the rectum in patients with rectal cancer who show a good clinical response after neoadjuvant chemoradiation. This phase II feasibility study compares two local treatment approaches contact x-ray brachytherapy versus extending the waiting period with or without local excision. The goal is to determine how often organ preservation can be achieved and to optimize treatment strategies for patients with a near-complete response or small residual tumor.
The study includes two experimental groups. In one group, contact x-ray brachytherapy is delivered as three 30 Gy fractions to the tumor within 14 weeks after completing chemoradiation, with two-week intervals between doses. Patients are monitored every three months afterward. The other group extends the waiting interval by 6 to 8 weeks after the initial response evaluation, with additional assessments to check for tumor response. Patients showing complete response enter a watch-and-wait approach, while those with small remaining lesions may receive local excision, followed by risk-based recommendations for further treatment.
Participants undergo regular clinical, radiological, and endoscopic assessments to monitor tumor response and detect any disease progression. The primary outcome is the rate of successful organ preservation one year after randomization. Secondary outcomes include treatment-related toxicity, postoperative complications, bowel and bladder function, quality of life, tumor regrowth, disease-free survival, and overall survival measured up to five years. An intensive follow-up program supports early detection of recurrence and timely surgical intervention if needed.
CONDITIONS
Brief Title
Organ Preservation in Rectal Cancer: Contact X-ray Brachytherapy vs Extending the Waiting Interval and Local Excision
Research Team
B
Barbara M Geubels, MD
B
Brechtje A Grotenhuis, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Histologically confirmed adenocarcinoma located above the dentate line and within 10 cm of the anal verge
Neoadjuvant short-course radiotherapy for intermediate rectal cancer or long-course chemoradiation for locally advanced rectal cancer according to Dutch guidelines
Near-complete clinical response or small residual tumor mass less than 3 cm
Both contact x-ray brachytherapy and local excision must be technically feasible
Age over 18 years
Written informed consent provided
You will not qualify if you...
Prior neoadjuvant or induction chemotherapy before or alongside (chemo)radiation
Radiation dose exceeding 50.4 Gy or boost dose on the primary tumor
Suspicious lymph nodes (yN1/N2) present at first response evaluation
Residual tumor size 3 cm or larger or involving over half of the rectal circumference
Inability to undergo contact x-ray brachytherapy or local excision
Medical conditions or frailty preventing completion or salvage total mesorectal excision (TME) surgery
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Neoadjuvant (Chemo)Radiation
Duration - Varies based on treatment type
Participants receive neoadjuvant short-course radiotherapy or long-course chemoradiation according to Dutch guidelines before randomization.
Multiple visits as part of standard care
First Response Evaluation
Duration - 1 to 2 weeks
Participants undergo radiological and endoscopic assessment 6-8 weeks after finishing neoadjuvant (chemo)radiation to determine clinical response.
1 visit (in-person)
Randomization to Experimental Treatment
Duration - Up to 14 weeks after neoadjuvant (chemo)radiation
Participants with a good, but not complete clinical response are randomized to one of two experimental treatment strategies to attempt organ preservation.
1 visit (in-person)
Treatment: Contact X-ray Brachytherapy Arm
Duration - Approximately 6 weeks
Participants receive three fractions of contact x-ray brachytherapy, each 30 Gy, with 2-week intervals between fractions.
3 treatment visits (in-person) with 2-week intervals
Treatment: Extended Waiting Interval Arm
Duration - 6 to 16 weeks including extended observation and possible local excision
Participants extend the waiting interval by 6-8 weeks after first response evaluation, followed by second or third response assessments. If residual lesion remains, local excision may be performed.
2 to 3 follow-up visits (in-person) including local excision if needed
Follow-up and Surveillance
Duration - Up to 5 years
Participants are monitored with response evaluations every 3 months to detect complete response, treatment failure, or disease progression, with watch-and-wait approach or surgery as needed.
Quarterly visits in the first year, less frequent later
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Comparing 3-Needle and 5-Needle Genicular Nerve Blocks for Pain and Quality of Life in Knee Osteoarthritis
Phase III Trial Comparing Short-Course Versus Long-Course Radiotherapy Followed by Immunotherapy and Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Community-Based Digital and Behavioral Management for Nocturia in Older Adults
Phase 2 Study on Safety and Effectiveness of Short Course Radiation and CAPOX Chemotherapy Before Surgery for T2 Rectal Cancer
Web-Based Light, Activity, and Sleep Program to Improve Quality of Life in Adults 70 and Older
Open-Label Phase 1 Study of DEM301 to Evaluate Safety and Dose in Adults With Advanced Metastatic Colorectal Cancer
Phase I-II Study of PD1 AB122 and Adenosine Receptor AB928 Antagonists with Chemotherapy After Short-Course Radiation for Rectal Cancer
Phase II Study of Beta-Hydroxybutyrate Supplementation with Short-Course Radiotherapy, Immunotherapy, and CAPEOX Chemotherapy in Locally Advanced Rectal Cancer
Randomized Study Comparing Low Volume Transanal Irrigation by Qufora48 IrriSedo MiniGo with Conservative Treatment in Adults with Low Anterior Resection Syndrome
Randomized Trial of Peer-Led CARE Intervention to Improve Health and Reduce Cardiovascular Risks in Women Ages 18 to 49 in Texas Communities
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Optimisation of Organ Preservation treatment strategies in patients with rectal cancer with a good clinical response after neoadjuvant (chemo)radiotherapy: Additional contact X-ray brachytherapy versus eXtending the observation period and local excision (OPAXX) - protocol for two multicentre, parallel, single-arm, phase II studies.
Barbara M Geubels, Baukelien van Triest, Femke P Peters...